

November 19, 2003

Hui Zhu, MD, ScD

Urology Section/Surgical Service
Louis Stokes Cleveland VA Medical Center
10701 East Boulevard
Cleveland, OH 44106
(216) 791 3800 x5146
hui.zhu@va.gov

**Professional
Appointments**

Physician, Glickman Urology Institute, Cleveland Clinic Foundation
March, 2014 to now
Section Chief , Urology Section/Surgery Service, Louis Stokes Cleveland VA
Medical Center, Cleveland, OH
October, 2009 to now
Staff Physician, Urology Section/Surgery Service, Louis Stokes Cleveland VA
Medical Center, Cleveland, OH
August, 2005 to now
Assistant Professor of Urologic Surgery and Attending Physician, Urology
Institute, University Hospitals Case Medical Center, Case Western Reserve
University, Cleveland, OH August, 2005 to February, 2014

**Education
and Training**

Memorial Sloan-Kettering Cancer Center, New York, NY
Urologic Oncology Fellowship July, 2004 – June, 2005
**Washington University Medical Center and Barnes-Jewish Hospital,
St. Louis, MO**
Urology Residency Program June, 1999 - June, 2004
Duke University School of Medicine, Durham, NC
M.D. August, 1996 - May, 1999
Massachusetts Institute of Technology, Cambridge, MA
Sc.D. in Radiological Sciences/Biomedical Engineering Sept., 1990 - August, 1996
The Rockefeller University, New York, NY
Graduate Study in Elementary Particle Physics Sept., 1989 - August, 1990
Peking University, Beijing, China
B.Sc. in Nuclear Physics Sept., 1985 - June, 1989

**Professional
Memberships**

Member, American Urological Association
2000
Board certified, American Board of Urology
2008

**Honors and
Awards**

Abstract on Prostate Cancer Selected for Media Release, American Urological
Association Annual Meeting, San Diego, CA 2013
3rd Best Research Abstract, 26th Engineering and Urology Society Annual Meeting,

November 19, 2003

Washington DC, 2011

American Urological Association-Chinese Urological Association Academic Exchange Scholar 2010

Department of Urology Teacher of the Year Award, University Hospitals Case Medical Center and Case Western University School of Medicine 2009

2nd. Prize for Clinical Research, I-70 Society for Research Competition, Mid-west Urology Residency Programs, 2003

1st. Prize for Clinical Research, I-70 Society for Research Competition, Mid-west Urology Residency Programs, 2002

Praecis Pharmaceuticals/AUA Gerald P. Murray Scholar from Washington University School of Medicine, 2002

Annenberg Outstanding Academic Achievement Award In Urology, Washington University Medical Center and Barnes-Jewish Hospital, 2001

Sigma Xi, The Scientific Research Honor Society

Alpha Sigma Nu, National Honor Society of Nuclear Science, MIT Chapter

Young Investigator Award, Radiation Research Society, 1993

**Current
Research
Support**

R21 CA 165398 (NCI/NIH) Zhu (mPI) 20% effort 11/1/2012 - 10/31/2014

Staging of Upper Tract Urothelial Cancer with Optical Coherence Tomography
The goal of the project is to establish optical criteria for ultrahigh resolution optical coherence tomography to grade and stage upper tract urothelial cancer

B4666R Damaser (PI) Zhu 5%
co-investigator 4/1/2012 - 3/31/2016

VA RR&D Merit Review

Wireless Implantable Pressure Monitor for Clinical Applications

The goal of this project is the initial development and testing of a miniature implantable device for long term wireless monitoring of pressure of the bladder and other internal organs.

**Completed
Research
Support**

Department of Veterans Affairs Career Development Award, Mechanisms of Post-radical Prostatectomy Urinary Incontinence Zhu 75% 7/2006 - 7/2010

B4666R Damaser (PI) Zhu 5% co-investigator 10/1/07 - 9/30/10

VA RR&D Merit Review

Wireless Implantable Pressure Monitor for Clinical Applications

The goal of this project is the initial development and testing of a miniature implantable device for long term wireless monitoring of pressure of the bladder and other internal organs.

1R01CA127493-01A2 Zhang (PI) Zhu 5% co-investigator 1/1/09 - 11/30/12

Urinary Continence and Quality of Life in Prostate Cancer Patients

The goal of this project is to improve continence, quality of life, and mood through enhancing adherence to PFME and self-management of bladder control. The secondary goals are to examine the physiological effects and cost effectiveness of the proposed interventions.

Johnson & Johnson / CERU Challenge Grant Award Zhu (PI)
2010-11

Grading and Staging of Bladder Cancer with Endoscopic Ultrahigh Resolution Optical Coherence Tomography (uhrOCT)

The goal of the project is to establish optical criteria for ultrahigh resolution optical coherence tomography to grade and stage bladder cancer, and most importantly, to establish uhrOCT as a tool for *in vivo* diagnosis of bladder cancer during transurethral resection of bladder cancer.

Publications

Zhang, A. Y., Gary, F., **Zhu, H.** What precipitated depression in African American cancer patients? Triggers and stressors. *Palliative & Supportive Care*, 2012 Mar 22:1-8.

Zhang AY, Gary F, **Zhu H.** Initial evidence of religious practice and belief in depressed african american cancer patients. *Open Nurs J.* 2013;7:1-5.

Maurice MJ, **Zhu H**, Stokes L. (2013) Sarcoidosis of the Prostate., *J Urol.* 2013 May 14.

Wang, Z., Lu, T., Du, L., Hu, Z., Zhuang, Q., Li, Y., Wang, C., **Zhu, H.**, Ye, Z. Plasmacytoid urothelial carcinoma of the urinary bladder: a clinical pathological study and literature review *Int J Clin Exp Pathol* 2012;5(6):601-608

Wang, H., Kang, W., **Zhu, H.**, MacLennan, G., Rollins, A. Three Dimensional Imaging of Ureter with Endoscopic Optical Coherence Tomography. *Urology* 77(5):1254-8. 2011 May.

Li, Y., Zhuang, Q., Hu Z., Wang, Z., **Zhu H.**, Ye, Z. A Modified Ureteroileal Anastomosis Technique for Bricker Urinary Diversion. *Urology* 78(5):1191-5 2011 Nov.

Shindel, A., **Zhu, H.**, Hovsepian, D., Brandes, S. Ureteric embolization with stainless-steel coils for managing refractory lower urinary tract fistula: a 12-year experience. *BJU Int.* 2006 Oct 9

Zhu, H., Roehl, K.A., Antenor, J.V., and Catalona, W.J. Is perineural invasion an independent predictor of biochemical progression in patients with organ confined disease after radical prostatectomy? Manuscript in preparation.

Zhu, H., Roehl, K.A., Antenor, J.V., and Catalona, W.J. Clinical value of longitudinal free-to-total PSA ratio slope to diagnosis of prostate cancer. *Journal*

of *Urology*. Supplement. 167(4): 208, #840, 2002 May, and 171(2): 661, *Journal of Urology*, 2004 February.

Zhu, H., Klutke, J.J., and Klutke, C.G. MRI findings with female prolapse. *Atlas of Urologic Clinic of North America*. 2(1):101-112, 2003 April.

Zhu, H., Roehl, K.A., Antenor, J.V., and Catalona, W.J. Should we biopsy men with PSA of 2.6-4.0 ng/ml? *Journal of Urology*. Supplement. 169(4): 208, #1072, 2003 April, and as Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. *Urology*. 66(3):547-51, 2005 Sep.

Zhu, H., Jain, R.K. and Baxter, L.T. Tumor pretargeting for radioimmunodetection and radioimmunotherapy. *Journal of Nuclear Medicine*. 39(1): 65-76, 1998 Jan.

Zhu, H., Baxter, L.T., and Jain, R.K. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies: Evaluation using a physiologically-based pharmacokinetic model. *Journal of Nuclear Medicine*. 38(5): 731-741, 1997 May.

Zhu, H., Melder, R.J., Baxter, L.T., and Jain, R.K. Physiologically-based kinetic model of effector cell biodistribution in mammals: Implications for adoptive immunotherapy. *Cancer Research*. 56(16): 3771-3781, 1996 Aug 15.

Baxter, L.T., **Zhu, H.**, Mackensen, D.G., Butler, W.F., and Jain, R.K. Biodistribution of monoclonal antibodies: scale-up from mouse to man using a physiologically-based pharmacokinetic model. *Cancer Research*. 55(20): 4611-4622, 1995 Oct 15.

Baxter, L.T., **Zhu, H.**, Mackensen, D.G., and Jain, R.K. Physiologically-based pharmacokinetic model for specific and non-specific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. *Cancer Research*. 54(6): 1517-1528, 1994 Mar 15.

National Conference Presentations

Maurice, M. and Zhu, H. Persistent Underutilization of Expectant Management for Prostate Cancer: 2000-2009. American Urological Association Annual Meeting, San Diego, CA, 2013 (**Selected for Media Release by the 2013 AUA Annual Meeting**)

Maurice, M. and Zhu, H. Systemic Chemotherapy Has Been Increasingly Adopted For Urothelial Carcinoma Over the Last Decade in the United States. American Urological Association Annual Meeting, San Diego, CA, 2013

Maurice, M. and Zhu, H. Radical Prostatectomy Became Increasingly Popular for All-risk Prostate Cancer Over the Last Decades in the United States. American Urological Association Annual Meeting, San Diego, CA, 2013

Kohut, R.M. and Zhu, H. Stage I Seminoma: Trends in Utilization of Adjuvant Therapy Following Orchiectomy Using the National Cancer Database. American Urological Association Annual Meeting, Atlanta, Georgia, 2012

Kohut, R.M. and Zhu, H. Treatment of Low Stage Urothelial Carcinoma of the Ureter: Trends in Utilization of Endoscopic Management. American Urological

Association Annual Meeting, Atlanta, Georgia, 2012

Fletcher, P., Majerus, S., Zhu, H., Boger, A., Garverick, S., Gustafson, K., and Damaser, M. Feasibility of Submucosal Bladder Pressure Sensing. American Urological Association Annual Meeting, Washington DC, 2011

Wang, H., Kang, W., Zhu, H., MacLennan, G., Rollin, A. Three-Dimensional Imaging of Ureter with Endoscopic Optical Coherence Tomography. American Urological Association Annual Meeting, Washington DC, 2011

Zhu, H., Roehl, K.A., Antenor, J.V., and Catalona, W.J. Clinical value of longitudinal free-to-total PSA ratio slope to diagnosis of prostate cancer. American Urological Association Annual Meeting, Orlando, Florida, 2002.

Zhu, H., Roehl, K.A., Antenor, J.V., and Catalona, W.J. Should we biopsy men with PSA of 2.6-4.0 ng/ml? American Urological Association Annual Meeting, Chicago, Illinois, 2003.

Roehl, K.A., Antenor, J.V., Zhu, H., and Catalona, W.J. Comparison of radical prostatectomy, radiotherapy, hormonal therapy, and watchful waiting for screen-detected prostate cancer: An Update. American Urological Association Annual Meeting, San Francisco, California, 2004.

Zhu, H., Roehl, K.A., Antenor, J.V., and Catalona, W.J. Is perineural invasion an independent predictor of biochemical progression in patients with organ confined disease after radical prostatectomy? American Urological Association Annual Meeting, San Francisco, California, 2004.

**Other
Selected
Presentations**

Minnillo, B.J., Zhu, H., Maurice, M.J., and Abouassaly, R. Trends in cytoreductive nephrectomy in the eras of immuno and targeted therapy. ASCO GU Symposium 2014. *J Clin Oncol* 32, 2014 (suppl 4; abstr 472)

Maurice, M.J., Abouassaly, R. and Zhu, H. A population-based study of expectant management utilization and its predictors for low-risk prostate cancer. ASCO GU Symposium 2014. *J Clin Oncol* 32, 2014 (suppl 4; abstr 68)

Maurice, M.J., Zhu, H., and Abouassaly, R. A population-based study of factors associated with post-prostatectomy radiation therapy utilization. ASCO GU Symposium 2014. *J Clin Oncol* 32, 2014 (suppl 4; abstr 182)

Ferry, E.K. and Zhu, H. Trends of multimodal therapy in high-stage penile cancer. ASCO GU Symposium 2014. *J Clin Oncol* 32, 2014 (suppl 4; abstr 370)

Ferry, E.K. and Zhu, H. Surgical management trends of penile cancer in the United States between 2000 and 2010. ASCO GU Symposium 2014. *J Clin Oncol* 32, 2014 (suppl 4; abstr 379)

Zhu, H., Melder, R.J., Baxter, L.T., and Jain, R.K. Physiologically-based kinetic model of effector cell biodistribution in mammals: Implications for adoptive immunotherapy. American Association for Cancer Research Meeting, Washington, D.C., 1996.

Zhu, H., Baxter, L.T., and Jain, R.K. Pharmacokinetics of monoclonal antibodies: scale-up from mouse to man. Biomedical Engineering Society Annual Meeting, Boston, MA, 1995.

Zhu, H., Baxter, L.T., and Jain, R.K. Limitations and potential of

November 19, 2003

radioimmunodetection and radioimmunotherapy determined using a physiologically-based pharmacokinetic model. *Monoclonal Antibodies and Cancer Therapy*, New York, NY, 1994.

Zhu, H., Baxter, L.T., and Jain, R.K. Physiologically-based kinetic model of effector cell biodistribution: Implication for adoptive immunotherapy. Radiation Research Society Annual Meeting, Nashville, TN, 1993.

Invited Talks Zhu, H. Sexual and Urinary Rehabilitation after Prostate Cancer Surgery. 2013 7th World Congress of the International Society of Physical and Rehabilitation Medicine, Beijing, China June 19, 2013

Zhu, H. Salvage Cryotherapy for Prostate Cancer after Radiation Treatment Failure. Tongji Hospital, Wuhan, China December 23, 2012

Zhu, H. Prostate Cancer Screening Controversy in USA

Zhu, H. From Pulse to Streptomycin: The Ideas of Clinical Trials. Chinese Urological Association Annual Meeting 2010, Xian, China October 13, 14, 2010

AUA-CUA Academic Exchange Scholar at Tongji Hospital, Wuhan, China August 3- September 3, 2010

Epidemiology and Diagnosis of Prostate Cancer in USA

Grading and Staging of Prostate Cancer in USA

Risk Adjusted Management of Prostate Cancer in USA

Resident Training in USA

Prostate Cancer Screening Controversy in USA

From Pulse to Streptomycin: The Ideas of Clinical Trials

Academic Services Liaison officer for ACS Cancer Program , LSCDVAMC Cancer Committee 2006 – UHCMC Urology Department QA Committee 2010 –

Teaching Services CPCP Preceptorship 2006 for Case Western University School of Medicine Year I student
Male Infertility: Evaluation and Treatment 1/29/2010 Lecture for Case Western Reserve School of Medicine Year I students